{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T01:20:08Z","timestamp":1794360008068,"version":"4.9.0"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:sec>\n            <jats:title>OBJECTIVE:<\/jats:title>\n            <jats:p>To compare pregnancy and neonatal outcomes in women with hyperandrogenic polycystic ovarian syndrome (PCOS) phenotypes compared with nonhyperandrogenic PCOS phenotypes.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>METHODS:<\/jats:title>\n            <jats:p>We conducted a retrospective cohort study of participants in the PPCOS (Pregnancy in Polycystic Ovary Syndrome) I and II randomized controlled trials; all of the participants met the National Institutes of Health diagnostic criteria for PCOS and were then sorted into three of the four Rotterdam criteria categories based on medical interview, demographics, physical examination, and laboratory data. The two hyperandrogenic (A and B) Rotterdam categories were compared with the nonhyperandrogenic phenotype of PCOS (phenotype D). Our outcomes of interest were clinical pregnancy, pregnancy loss, live birth, obstetric complications (including preterm labor, preeclampsia, gestational diabetes, intrauterine growth restriction, and premature rupture of membranes), and neonatal outcomes (including jaundice, respiratory distress syndrome, neonatal hospitalization, and neonatal infection).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>RESULTS:<\/jats:title>\n            <jats:p>Of the 1,376 participants included in the study, 1,249 (90.8%) had hyperandrogenic PCOS phenotypes compared with 127 (9.2%) nonhyperandrogenic PCOS (nonhyperandrogenic PCOS). Compared with participants with nonhyperandrogenic PCOS, those with hyperandrogenic PCOS had higher body mass index (BMI) (35.5\u00b18.9 vs 31.9\u00b19.3 kg\/m<jats:sup>2<\/jats:sup>, <jats:italic toggle=\"yes\">P<\/jats:italic>&lt;.001), fasting insulin (21.6\u00b127.7 vs 14.7\u00b115.0 micro-international units\/mL, <jats:italic toggle=\"yes\">P<\/jats:italic>&lt;.001), and homeostatic model assessment for insulin resistance score (5.01\u00b19.1 vs 3.4\u00b14.1, <jats:italic toggle=\"yes\">P<\/jats:italic>=.0002). Age and race were similar between groups. Months attempting pregnancy were greater in participants with hyperandrogenic PCOS compared with nonhyperandrogenic PCOS (41.8\u00b137.3 vs 33.9\u00b132.0). The proportion of participants who achieved pregnancy (29.9% vs 40.2%, <jats:italic toggle=\"yes\">P<\/jats:italic>=.02) and live birth rates (20.1% vs 33.1%, <jats:italic toggle=\"yes\">P<\/jats:italic>=.001) were lower among those with hyperandrogenic PCOS compared with nonhyperandrogenic PCOS, although pregnancy loss rates did not differ significantly (23.9% vs 32.3%, <jats:italic toggle=\"yes\">P<\/jats:italic>=.06). The hyperandrogenic PCOS group had lower odds of live birth compared with the nonhyperandrogenic PCOS group (odds ratio [OR] 0.51, CI, 0.34\u20130.76), even after adjusting for BMI (adjusted odds ratio [aOR] 0.59, CI, 0.40\u20130.89). The hyperandrogenic PCOS group also had lower odds of achieving pregnancy compared with the nonhyperandrogenic PCOS group (OR 0.63, CI, 0.44\u20130.92); however, this association was no longer significant after adjusting for BMI (aOR 0.74, CI, 0.50\u20131.10). The overall low prevalence of prenatal complications and neonatal outcomes precluded a meaningful comparison between the two groups.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSION:<\/jats:title>\n            <jats:p>Participants with hyperandrogenic PCOS achieved lower rates of pregnancy and live birth compared with those with nonhyperandrogenic PCOS. Evaluating distinct PCOS phenotypes may allow for individualized guidance regarding the probability of pregnancy and live birth.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CLINICAL TRIALS REGISTRATION:<\/jats:title>\n            <jats:p>\n                                 ClinicalTrials.gov, NCT00068861 and NCT00718186.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/aog.0000000000005702","type":"journal-article","created":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T06:49:37Z","timestamp":1724395777000},"page":"543-549","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":17,"title":["Correlation of Polycystic Ovarian Syndrome Phenotypes With Pregnancy and Neonatal Outcomes"],"prefix":"10.1097","volume":"144","author":[{"given":"Jessica L.","family":"Chan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard S.","family":"Legro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Eisenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margareta D.","family":"Pisarska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanette","family":"Santoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,8,22]]},"reference":[{"key":"R1-20250502","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1210\/clinem\/dgad463","article-title":"Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome","volume":"108","author":"Teede","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"R2-20250502","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/humrep\/deh098","article-title":"Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS)","volume":"19","year":"2004","journal-title":"Hum Reprod"},{"key":"R3-20250502","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ejogrb.2013.05.019","article-title":"Serum anti-Mullerian hormone levels in the main phenotypes of polycystic ovary syndrome","volume":"170","author":"Sahmay","year":"2013","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"R4-20250502","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1056\/NEJMoa063971","article-title":"Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome","volume":"356","author":"Legro","year":"2007","journal-title":"N Engl J Med"},{"key":"R5-20250502","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1056\/NEJMoa1313517","article-title":"Letrozole versus clomiphene for infertility in the polycystic ovary syndrome","volume":"371","author":"Legro","year":"2014","journal-title":"N Engl J Med"},{"key":"R6-20250502","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/BF00280883","article-title":"Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man","volume":"28","author":"Matthews","year":"1985","journal-title":"Diabetologia"},{"key":"R7-20250502","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1161\/CIRCULATIONAHA.109.192644","article-title":"Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity","volume":"120","author":"Alberti","year":"2009","journal-title":"Circulation"},{"key":"R8-20250502","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1016\/j.fertnstert.2014.01.023","article-title":"Cluster analysis of cardiovascular and metabolic risk factors in women of reproductive age","volume":"101","author":"Tzeng","year":"2014","journal-title":"Fertil Steril"},{"key":"R9-20250502","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.fertnstert.2016.12.017","article-title":"Normo- and hyperandrogenic women with polycystic ovary syndrome exhibit an adverse metabolic profile through life","volume":"107","author":"Pinola","year":"2017","journal-title":"Fertil Steril"},{"key":"R10-20250502","doi-asserted-by":"crossref","first-page":"e1003132","DOI":"10.1371\/journal.pmed.1003132","article-title":"Distinct subtypes of polycystic ovary syndrome with novel genetic associations: an unsupervised, phenotypic clustering analysis","volume":"17","author":"Dapas","year":"2020","journal-title":"PLoS Med"},{"key":"R11-20250502","doi-asserted-by":"crossref","first-page":"e1558","DOI":"10.1002\/wsbm.1558","article-title":"Hyperandrogenism and Polycystic ovary syndrome: effects in pregnancy and offspring development","volume":"14","author":"Abruzzese","year":"2022","journal-title":"WIREs Mech Dis"},{"key":"R12-20250502","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1016\/j.fertnstert.2011.03.021","article-title":"Endometrial gene expression in the window of implantation is altered in obese women especially in association with polycystic ovary syndrome","volume":"95","author":"Bellver","year":"2011","journal-title":"Fertil Steril"},{"key":"R13-20250502","doi-asserted-by":"crossref","first-page":"R35","DOI":"10.1530\/JME-16-0027","article-title":"Regulation of androgen action during establishment of pregnancy","volume":"57","author":"Gibson","year":"2016","journal-title":"J Mol Endocrinol"},{"key":"R14-20250502","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1016\/j.fertnstert.2009.01.096","article-title":"Effects of testosterone and metformin on glucose metabolism in endometrium","volume":"93","author":"Zhang","year":"2010","journal-title":"Fertil Steril"},{"key":"R15-20250502","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1093\/humrep\/dep444","article-title":"Metformin influence on hormone levels at birth, in PCOS mothers and their newborns","volume":"25","author":"Carlsen","year":"2010","journal-title":"Hum Reprod"},{"key":"R16-20250502","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/j.fertnstert.2020.02.005","article-title":"Elevated maternal androgen is associated with dysfunctional placenta and lipid disorder in newborns of mothers with polycystic ovary syndrome","volume":"113","author":"Sun","year":"2020","journal-title":"Fertil Steril"},{"key":"R17-20250502","first-page":"2829","article-title":"Placental characteristics in women with polycystic ovary syndrome","volume":"30","author":"Koster","year":"2015","journal-title":"Hum Reprod"},{"key":"R18-20250502","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1093\/humupd\/dmaa051","article-title":"Endometrial function in women with polycystic ovary syndrome: a comprehensive review","volume":"27","author":"Palomba","year":"2021","journal-title":"Hum Reprod Update"},{"key":"R19-20250502","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1080\/09513590.2019.1631278","article-title":"Comparing pregnancy, childbirth, and neonatal outcomes in women with different phenotypes of polycystic ovary syndrome and healthy women: a prospective cohort study","volume":"36","author":"Foroozanfard","year":"2020","journal-title":"Gynecol Endocrinol"},{"key":"R20-20250502","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1016\/j.fertnstert.2009.10.043","article-title":"Pregnancy in women with polycystic ovary syndrome: the effect of different phenotypes and features on obstetric and neonatal outcomes","volume":"94","author":"Palomba","year":"2010","journal-title":"Fertil Steril"},{"key":"R21-20250502","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/1477-7827-11-56","article-title":"Obstetric complications in women with polycystic ovary syndrome: a systematic review and meta-analysis","volume":"11","author":"Qin","year":"2013","journal-title":"Reprod Biol Endocrinol"}],"container-title":["Obstetrics &amp; Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/AOG.0000000000005702","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T00:00:55Z","timestamp":1746230455000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/AOG.0000000000005702"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,22]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/aog.0000000000005702","relation":{},"ISSN":["0029-7844"],"issn-type":[{"value":"0029-7844","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8,22]]},"assertion":[{"value":"2024-02-21","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-09","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}